Ready-to-use AAV Retrograde particles produced from hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from CAG-NLS-GFP (#104061). In addition to the viral particles, you will also receive purified CAG-NLS-GFP plasmid DNA. CAG-driven NLS-GFP expression. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.eB particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pAAV-CAG-eYFP (#104055). In addition to the viral particles, you will also receive purified pAAV-CAG-eYFP plasmid DNA. CAG-driven eYFP expression control. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV PHP.V1 particles produced from pAAV-CAG-DIO-EYFP (#104052). In addition to the viral particles, you will also receive purified pAAV-CAG-DIO-EYFP plasmid DNA. CAG-driven, Cre-dependent expression of EYFP. These AAV were produced with the PHP.V1 serotype, which permits efficient transduction of brain vascular cells. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from AAV-hSyn-mCherry-P2A-Cre-WPRE (#107312). In addition to the viral particles, you will also receive purified AAV-hSyn-mCherry-P2A-Cre-WPRE plasmid DNA. hSyn-driven expression of mCherry and Cre (physically separate). These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV5 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV1 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV8 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV9 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV2 particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV preparations are suitable purity for injection into animals.

Ready-to-use AAV Retrograde particles produced from pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP (#112677). In addition to the viral particles, you will also receive purified pOTTC1032 - pAAV EF1a Nuc-flox(mCherry)-EGFP plasmid DNA. EF1a-driven, Cre-dependent color switch. This AAV directs expression of nuclear mCherry in the absence of Cre. In the presence of Cre, nuclear EGFP (and not mCherry) will be expressed. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

E. coli MG1655 strain with knockout of endogenous Type I-E CRISPR Cas system

Expression of dCas9 gene under the control of a Ptet promoter in the E. coli chromosome

Expresses RFP from the chromosome of Corynebacterium glutamicum ATCC 13032 (ptac promoter unrepressed; no LacI present)

Expression of dCas9 gene under the control of a Ptet promoter in the E. coli chromosome

Expression of dCas9 gene under the control of a Ptet promoter in the E. coli chromosome

Expression of dCas9 gene under the control of a weak Ptet promoter in the E. coli chromosome

Escherichia coli DH10B DAP-auxotrophic strain containing an integrated RK2/RP4 mobilization vector to conjugate plasmids with an IncP origin of transfer (modified pTA-Mob 2.0, AddGene Plasmid #149662)

Plasmid for CRISPRi; oriV(pRO1600/ColE1), xylS (cured of BsaI-sites), Pm→ Sp dCas9, PEM7 →sgRNA; SmR/SpR